Therapeutic strategy for HER-2-positive advanced breast cancer / 中国肿瘤临床
Chinese Journal of Clinical Oncology
;
(24): 412-417, 2016.
Article
Dans Chinois
| WPRIM
| ID: wpr-490312
ABSTRACT
Patients with HER-2-positive advanced breast cancer were associated with poor prognosis. Meanwhile, HER-2-targeted ther-apy has dramatically improved survival and prognosis among breast cancer patients. Over the years, multiple HER-2-targeting drugs stepped into clinical practice, and the targeted agents are now considered as the standard of care in the first-line setting and beyond. This review basically summarizes the importance of HER-2-targeted therapy, the significance of the clinical trial results, and the clinical practice guidelines for the management of patients with HER-2-positive advanced breast cancer.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Type d'étude:
Guide de pratique
langue:
Chinois
Texte intégral:
Chinese Journal of Clinical Oncology
Année:
2016
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS